BRIDGEWATER, N.J., Oct. 24,
2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
INSM), a global biopharmaceutical company, today announced a
collaboration with Google Cloud to transform the drug discovery,
development, and commercialization landscape of the life sciences
industry through the use of generative AI. This alliance will
harness the power of Google Cloud's cutting-edge AI technology and
Insmed's expertise in serious and rare diseases with a clear goal
of reducing the time and increasing the efficiency of developing
and delivering new medicines to appropriate patients.
The collaboration focuses on four key aspects of the life
sciences industry—drug discovery, drug development, drug
commercialization, and enabling functions—and has already
identified one to three projects under each area for completion
within the next 18 months, with multiple additional programs to
follow.
"At the heart of this partnership is our shared vision to
leverage the immense potential of generative AI to reduce the time
and cost associated with bringing life-changing therapies to
patients with serious and rare conditions," said Shweta Maniar, global director of Life Science
Strategy & Solutions, Google Cloud. "Insmed has a clear focus
on improving patient outcomes, and we look forward to the potential
impact these efforts may have on patients and on the life sciences
industry at large."
Insmed has built a generative AI search capability using Vertex
AI Search trained on its internal documentation, as well as
separate functionality that enables indexed access to available,
external medical publications.
"This collaboration represents a multi-year commitment to bring
about real change to the drug development process," said
Will Lewis, chair and chief
executive officer of Insmed. "Reducing the timeline for drug
development and enhancing the delivery of drugs to appropriate
patients would represent a major breakthrough for the application
of AI in the life sciences ecosystem. Google Cloud is the clear
partner of choice in this effort and we are thrilled to work
together to pursue a future where groundbreaking therapies are
developed with unprecedented speed and precision."
"Insmed is using Google Cloud infrastructure and AI technology
to power this transformation leveraging already available AI
modules," said Mark Pellegrino,
chief information officer of Insmed. "The potential to extend this
kind of technology to areas like drafting a clinical study report,
which is incredibly labor-intensive, has profound implications for
improving the efficiency and accuracy of how our industry delivers
data. From the day we began to explore possibilities, Google Cloud
has been in lockstep with Insmed's ambition to transform the life
sciences ecosystem."
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United States, Europe,
and Japan to treat a chronic, debilitating lung disease.
The Company is progressing a robust pipeline of investigational
therapies targeting areas of serious unmet need, including
neutrophil-mediated inflammatory diseases and rare pulmonary
disorders. Insmed is also advancing an early-stage research engine
encompassing a wide range of technologies and modalities, including
artificial intelligence-driven protein engineering, gene therapy,
and protein manufacturing. Insmed is headquartered
in Bridgewater, New Jersey, with additional offices and
research locations throughout the United States, Europe,
and Japan. Visit www.insmed.com to learn more.
Forward-looking
Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. "Forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995, are statements that are not
historical facts and involve a number of risks and uncertainties.
Words herein such as "may," "will," "should," "could," "would,"
"expects," "plans," "anticipates," "believes," "estimates,"
"projects," "predicts," "intends," "potential," "continues," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) may
identify forward-looking statements.
The forward-looking statements in this press release are based
upon the Company's current expectations and beliefs, and involve
known and unknown risks, uncertainties and other factors, which may
cause the Company's actual results, performance and achievements
and the timing of certain events to differ materially from the
results, performance, achievements or timings discussed, projected,
anticipated or indicated in any forward-looking statements. Such
risks, uncertainties and other factors include, among others, the
Company's ability to utilize AI to impact the costs and timelines
associated with drug discovery, development and
commercialization.
The Company may not actually achieve the results, plans,
intentions or expectations indicated by the Company's
forward-looking statements because, by their nature,
forward-looking statements involve risks and uncertainties because
they relate to events and depend on circumstances that may or may
not occur in the future. For additional information about the risks
and uncertainties that may affect the Company's business, please
see the factors discussed in Item 1A, "Risk Factors," in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2022 and any subsequent
Company filings with the Securities and Exchange Commission
(SEC).
The Company cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date of
this press release. The Company disclaims any obligation, except as
specifically required by law and the rules of the SEC, to publicly
update or revise any such statements to reflect any change in
expectations or in events, conditions or circumstances on which any
such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-and-google-cloud-collaborate-to-transform-the-lives-of-patients-by-harnessing-the-power-of-ai-301965180.html
SOURCE Insmed Incorporated